Particle.news

Download on the App Store

Mankind Pharma Posts Profit Decline but Outperforms Estimates with Strong Revenue Growth

The pharmaceutical giant reported a 10.7% dip in Q4 net profit, driven by integration costs, while revenue surged 27% and exports soared 88% for FY25.

Image
Mankind Pharma

Overview

  • Mankind Pharma's Q4 FY25 net profit dropped 10.7% year-over-year to ₹4.21 billion, but exceeded analysts’ expectations of ₹3.60 billion.
  • Quarterly revenue rose 27% to ₹30.79 billion, fueled by robust growth in chronic therapies and consumer healthcare demand.
  • The company completed the integration of its ₹1.6 billion acquisition of Bharat Serums and Vaccines, which bolstered revenue but pressured margins, with EBITDA margin declining to 22.2% from 24.2%.
  • Exports surged 88% year-over-year to ₹1,532 crore for FY25, contributing to a 19% rise in total annual revenue to ₹12,207 crore.
  • Mankind Pharma retained its position as India’s top pharmaceutical company by prescription count for the eighth consecutive year.